APA

Zhu J., Wang Y., Duan J., Bai H., Wang Z., Wei L., Zhao J., Zhuo M., Wang S., Yang L., An T., Wu M. & Wang J. (20130523). DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer. : Journal of experimental & clinical cancer research : CR.

Chicago

Zhu Jian, Wang Yuyan, Duan Jianchun, Bai Hua, Wang Zhijie, Wei Lai, Zhao Jun, Zhuo Minglei, Wang Shuhang, Yang Lu, An Tongtong, Wu Meina and Wang Jie. 20130523. DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer. : Journal of experimental & clinical cancer research : CR.

Harvard

Zhu J., Wang Y., Duan J., Bai H., Wang Z., Wei L., Zhao J., Zhuo M., Wang S., Yang L., An T., Wu M. and Wang J. (20130523). DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer. : Journal of experimental & clinical cancer research : CR.

MLA

Zhu Jian, Wang Yuyan, Duan Jianchun, Bai Hua, Wang Zhijie, Wei Lai, Zhao Jun, Zhuo Minglei, Wang Shuhang, Yang Lu, An Tongtong, Wu Meina and Wang Jie. DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer. : Journal of experimental & clinical cancer research : CR. 20130523.